Intraperitoneal Paclitaxel Is Useful as Adjuvant Chemotherapy for Advanced Gastric Cancer with Serosal Exposure

Publisher： Karger

E-ISSN： 1662-6575|7|1|58-64

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.7, Iss.1, 2014-01, pp. : 58-64

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Retrospective Analysis of Adjuvant Intraperitoneal Chemotherapy Effect Prognosis of Resectable Gastric Cancer

By  

Oncology, Vol. 80, Iss. 5-6, 2011-07 ,pp. : 289-295

Karger

Access to resources Recommend Favorite

Phase I Pharmacokinetic Study of Weekly Intravenous and Intraperitoneal Paclitaxel Combined with S-1 for Advanced Gastric Cancer

By  

Oncology, Vol. 76, Iss. 5, 2009-03 ,pp. : 311-314

Karger

Access to resources Recommend Favorite

Weekly Intravenous and Intraperitoneal Paclitaxel Combined with S-1 for Malignant Ascites due to Advanced Gastric Cancer

By  

Oncology, Vol. 78, Iss. 1, 2010-03 ,pp. : 40-46

Karger

Access to resources Recommend Favorite

Early Postoperative Intraperitoneal Chemotherapy with Mitomycin C, 5-Fluorouracil and Cisplatin for Advanced Gastric Cancer

By  

Oncology, Vol. 60, Iss. 1, 2000-12 ,pp. : 24-30

Karger

Access to resources Recommend Favorite

A phase II trial of perioperative chemotherapy involving a single intraperitoneal administration of paclitaxel followed by sequential S‐1 plus intravenous paclitaxel for serosa‐positive gastric cancer

By  

JOURNAL OF SURGICAL ONCOLOGY, Vol. 111, Iss. 8, 2015-06 ,pp. : 1041-1046

John Wiley & Sons Inc

Access to resources Recommend Favorite